Business Context and Reporting Period
Company: Metagenomi Therapeutics, Inc. (MGX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Metagenomi is an in vivo genome editing company developing curative genetic medicines. The company recently changed its name from Metagenomi, Inc. to Metagenomi Therapeutics, Inc. in Q1 2026 to reflect a strategic evolution focused on advancing later-stage preclinical programs. The company operates as a single segment and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Collaboration Revenue | $(257) | $991 | $12,640 |
| Total Operating Expenses | $28,516 | $54,351 | $61,447 |
| Net Loss | $(27,482) | $(50,541) | $(44,947) |
| Net Loss Per Share (Basic & Diluted) | $(0.73) | $(1.34) | $(1.21) |
| Cash, Cash Equivalents & Restricted Cash (Balance Sheet) |
$43,421 (as of June 30, 2026) | ||
| Available-for-Sale Marketable Securities (Balance Sheet) |
$81,636 (as of June 30, 2026) | ||
| Total Liquidity (Cash + Securities) |
$120,700 (as of June 30, 2026) | ||
| Accumulated Deficit | $(361,411) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased significantly to $0.3 million (negative) for the three months ended June 30, 2026, compared to $8.5 million in the prior year period. This was primarily due to a $2.6 million cumulative catch-up adjustment recorded as a reduction to revenue following a modification to the Ionis collaboration agreement in April 2026. For the six months ended June 30, 2026, revenue was $1.0 million, down from $12.6 million in the prior year.
- Operating Expenses: Total operating expenses decreased by $7.1 million (11.5%) for the six months ended June 30, 2026, compared to the prior year period. This reduction was driven by decreases in employee-related expenses ($5.8 million), facilities and overhead costs ($1.4 million), and stock-based compensation ($1.0 million), partially offset by an increase in R&D supplies and services ($2.3 million).
- Net Loss Increase: Net loss increased to $50.5 million for the six months ended June 30, 2026, from $44.9 million in the prior year period, largely reflecting the revenue reduction and continued investment in R&D.
- Investment Impairment: The company recorded a non-cash lease impairment expense of $0.6 million in Q2 2026 related to a sublease of office space. Additionally, the estimated fair value of investments in Affini-T Therapeutics, Inc. remains at zero following Affini-T's assignment for the benefit of creditors in September 2025.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes that existing cash, cash equivalents, and available-for-sale marketable securities of $120.7 million as of June 30, 2026, are sufficient to fund operations for at least the next 12 months. The company has an "At-The-Market" (ATM) Sales Agreement with Jefferies LLC for up to $75.0 million, though no shares have been sold under this agreement to date.
- Pipeline Progress:
- MGX-001 (Hemophilia A): Preclinical data in non-human primates demonstrated curative Factor VIII activity. The company completed a pre-IND meeting in Q4 2025 and remains on track for an IND submission in Q4 2026, with clinical trials expected to initiate in 2027.
- Ionis Collaboration: The company is in Wave 1 of the collaboration, focusing on four cardiometabolic targets (APOC3, TTR, AGT, and one undisclosed). All targets are in the lead optimization phase.
- Strategic Reprioritization: In late 2025, the company decided to focus resources on lead programs with the highest probability of success and well-understood biology, while maintaining financial discipline.
- Key Risks:
- Capital Needs: The company has incurred significant losses since inception and expects to continue doing so. It will require substantial additional funding to advance clinical trials and commercialize products.
- Securities Litigation: A class action lawsuit (Vreeland v. Metagenomi Inc. et al.) regarding the company's IPO and collaboration with Moderna is currently in discovery. The court granted-in-part and denied-in-part the defendants' motion to dismiss in March 2026.
- Regulatory Uncertainty: As a novel genome editing company, the regulatory pathway is evolving. The FDA has issued new draft guidance documents in 2026 regarding cell and gene therapy products.
Investor Verification Checklist
- Revenue Recognition: Verify the impact of the April 2026 Ionis agreement modification and the $2.6 million revenue reduction on future revenue recognition schedules.
- Cash Runway: Confirm the $120.7 million liquidity position and the timeline for potential additional capital raises given the $50.5 million net loss for the first half of 2026.
- MGX-001 Timeline: Monitor the Q4 2026 IND submission target and any potential delays due to regulatory feedback or additional preclinical data requirements.
- Legal Proceedings: Track the status of the Vreeland securities class action lawsuit and potential financial exposure.
- Collaboration Status: Review the status of the Ionis Wave 1 targets and the potential for Wave 2 target selection fees ($15M-$30M) to be triggered.